The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ICML 2025 | The impact of TP53 mutations on the prognosis of patients with Waldenström’s macroglobulinemia
Steven Treon, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, comments on the significance of TP53 alterations in Waldenström’s macroglobulinemia, highlighting that patients with TP53 mutations or deletions at 17p are indicative of high-risk disease. Dr Treon emphasizes the need for a more comprehensive action plan for these patients. This interview took place during the 18th International Conference on Malignant Lymphoma (18-ICML) in Lugano, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So we recognize that the last international workshop on Waldenström’s that patients who have TP53 alterations and that includes both mutations in TP53 but also loss, 17p deletions, are very very indicative of high-risk patients. And what we’re also seeing is that patients who had received perhaps earlier in their course of therapy alkylating agents also appear to be at higher risk of acquiring these mutations...
So we recognize that the last international workshop on Waldenström’s that patients who have TP53 alterations and that includes both mutations in TP53 but also loss, 17p deletions, are very very indicative of high-risk patients. And what we’re also seeing is that patients who had received perhaps earlier in their course of therapy alkylating agents also appear to be at higher risk of acquiring these mutations. And that’s why I think, you know, the last consensus panel that was held at the workshop in Prague identified TP53 alterations as being indicative of high-risk disease and worthy of us concentrating. Now, do we have really an action plan around these? A little bit. We know that zanubrutinib is more active than ibrutinib. We tend to prioritize zanubrutinib for treating patients with TP53 alterations, but I do think more is needed. And perhaps now with the excitement around cellular therapies, we may be seeing a path forward for treating and managing these patients with high-risk disease.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
